Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Apolo on the Combination of Cabozantinib Plus Nivolumab in Urothelial Carcinoma

Andrea B. Apolo, MD
Published: Thursday, Jul 06, 2017



Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the combination of cabozantinib (Cabometyx) plus nivolumab (Opdivo) in patients with urothelial carcinoma.

There is a study investigating cabozantinib plus nivolumab and cabozantinib plus nivolumab plus ipilimumab (Yervoy) in patients with urothelial carcinoma and other genitourinary malignancies, states Apolo. Sixty-six patients have been enrolled with data being presented on 46 patients with a median follow-up of 12.4 months.

The overall response rate (ORR) for the entire cohort is 34%, with the bladder cancer cohort seeing an ORR of 44%. The median overall survival has not yet been met and the progression-free survival is 6.4 months, explains Apolo.



Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the combination of cabozantinib (Cabometyx) plus nivolumab (Opdivo) in patients with urothelial carcinoma.

There is a study investigating cabozantinib plus nivolumab and cabozantinib plus nivolumab plus ipilimumab (Yervoy) in patients with urothelial carcinoma and other genitourinary malignancies, states Apolo. Sixty-six patients have been enrolled with data being presented on 46 patients with a median follow-up of 12.4 months.

The overall response rate (ORR) for the entire cohort is 34%, with the bladder cancer cohort seeing an ORR of 44%. The median overall survival has not yet been met and the progression-free survival is 6.4 months, explains Apolo.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x